Agencies, delegations and associations at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
81 agencies, delegations and associations are at BIO-Europe 2026 — 36 presentations on the program. Most represented: European Medicines Agency (5 on the program), EUCOPE (3 on the program), European Commission (3 on the program). 68 of them have their own page in this guide. As of Sep 29, 2026.
Track
Top represented
Showing 1–16 of 81 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
European Medicines Agency Amsterdam, Netherlands | |
EU agency that evaluates and supervises medicines for human and veterinary use. | Panel Mon Nov 9 11:00–11:45 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech Panel Tue Nov 10 13:00–13:45 Aligning with Regulators to Propel Innovation What help and incentives the European Medicines Agency offers developers of new treatments, and how to use them on the road to approval. Panel Tue Nov 10 14:00–14:45 Harnessing Regulatory Sandboxes to Drive Innovation in Novel Therapeutics & Technologies How regulatory sandboxes, where regulators let new products be tested under adjusted rules, could support new therapies and health technologies in Europe. Panel Wed Nov 11 10:00–10:45 AI Regulations: Driving Innovation While Navigating Compliance What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
EUCOPE Brussels, Belgium | |
Trade association representing small and mid-sized innovative pharmaceutical and biotech companies in Europe. | Panel Tue Nov 10 10:30–10:55 Addressing Unmet Medical Needs in Europe’s Evolving Pharmaceutical Landscape How regulators judge which diseases lack good treatments, which faster approval routes apply, and whether recent EU drug law changes have helped. Panel Wed Nov 11 13:00–13:45 HTA Regulation: Early Insights and Reimbursement Implications Early lessons from the EU's new joint reviews of how much new drugs help patients, and whether they ease or hinder patient access. Panel Wed Nov 11 10:00–10:45 Most Favoured Nations: A Game-Changer for Biotech Dealmaker? How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans. |
European Commission Brussels, Belgium | |
Executive body of the European Union, proposing legislation and running EU programmes, including health, medicines and research policy. | Panel Tue Nov 10 09:00–09:45 Accelerating Innovation and Market Exclusivity Through Regulatory Incentives How updated EU drug laws and the Biotech Act change how long new medicines are shielded from competing copies, compared with rules elsewhere. Panel Wed Nov 11 09:00–09:45 From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance. |
Biotechnology Innovation Organization (BIO) Washington, District of Columbia | |
Trade association representing biotechnology companies, and organizer of the BIO International Convention. | Keynote Mon Nov 9 10:45–11:00 Panel Wed Nov 11 09:30–09:55 The State of Biopharma Deal-Making in 2026: Global Trends & Strategic Shifts What the numbers show about this year's drug licensing deals and acquisitions, cross-border partnerships, and the disease areas buyers favor. |
Life Science Nord Hamburg, Germany | ○Supporter |
Life sciences industry cluster for Hamburg and Schleswig-Holstein in northern Germany. | Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy |
One Nucleus Cambridge, United Kingdom | ○Supporter |
Membership organization for life sciences and healthcare companies in Cambridge, London and the wider UK. | Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy |
○Supporter | |
Network organization for the biotech sector in Munich and Bavaria, supporting startups and companies. | Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where cell and gene therapies stand today, what recent clinical and sales data show, and how funding and partnerships are changing. |
◆Platinum Sponsor | |
Health innovation cluster of Wallonia, Belgium, connecting biotech and medtech companies, universities and research centres. | Talk Wed Nov 11 10:30–11:00 From Innovation to Scalable Manufacturing: Closing the Gap Biotechs, researchers and contract manufacturers discuss what it takes to scale a new therapy into a product made reliably under strict quality rules. |
Germany Trade & Invest Berlin, Germany | ◆Gold Sponsor |
Germany's economic development agency promoting the country as a business location; Health Made in Germany is its healthcare industry initiative. | Panel Tue Nov 10 09:30–09:55 Biopharma Ecosystem Germany: Spotlight on Innovation Drivers Ready for Take-Off Five teams from Germany's biotech scene, which spans university research, companies, drug manufacturing and healthcare, show their work and its impact. |
Government of Canada Ottawa, Canada | ○Supporter |
Canada's federal government, represented through its Trade Commissioner Service, which helps Canadian companies do business abroad. | Panel Mon Nov 9 14:00–14:25 Get in the Mix with Canada’s Picks: Innovation in Life Sciences Selected Canadian companies present their health technologies, alongside an overview of Canada's life sciences sector and its partnership opportunities. |
JETRO Tokyo, Japan | ◆Platinum Sponsor |
Japan External Trade Organization, the government agency promoting trade and investment between Japan and other countries. | Talk Tue Nov 10 10:45–11:00 Unlocking Japan: Opportunities for Global Biotech to Access and Navigate the Japanese Market How foreign biotechs can get government-backed help finding partners and investors in Japan, and what its two major biotech regions offer. |
Life Sciences BC Vancouver, Canada | ○Supporter |
Industry association representing the life sciences sector in British Columbia, Canada. | Panel Mon Nov 9 14:00–14:25 Get in the Mix with Canada’s Picks: Innovation in Life Sciences Selected Canadian companies present their health technologies, alongside an overview of Canada's life sciences sector and its partnership opportunities. |
SPRIND Leipzig, Germany | ◆Gold Sponsor |
Germany's Federal Agency for Breakthrough Innovation, funding and building ventures around high-risk, high-impact technologies. | Panel Mon Nov 9 15:00–15:25 |
B BackingHerVenture | |
German non-profit association supporting women founders in healthcare and life sciences through leadership programs and networks. | Panel Tue Nov 10 13:00–13:45 Building Biotech Companies, Not Just Funding Them How investors now build biotechs from scratch around university science, supplying leaders and shared resources, and whether that can be made repeatable. |
BI BioInnovation Institute Copenhagen, Denmark | |
Non-profit life science incubator founded by the Novo Nordisk Foundation, funding and housing early-stage startups. | Panel Tue Nov 10 13:00–13:45 Building Biotech Companies, Not Just Funding Them How investors now build biotechs from scratch around university science, supplying leaders and shared resources, and whether that can be made repeatable. |
Non-profit research arm of DEBRA Austria driving translational research and clinical development for epidermolysis bullosa. | Panel Wed Nov 11 13:00–13:45 Beyond the surface: The rise and future of dermatology Why skin medicine is drawing investment, from biologics for inflammatory and rare skin diseases to cosmetic treatments, and which deals are emerging. |
Instantly find 20 buyers from agencies, delegations and associations
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction